[Intravitreal ranibizumab for management of choroidal neovascularization secondary to angioid streaks: a case report]

J Fr Ophtalmol. 2013 Jan;36(1):e5-9. doi: 10.1016/j.jfo.2012.04.004. Epub 2013 Jan 8.
[Article in French]

Abstract

Angioid streaks are biomicroscopically observable manifestations that frequently lead to choroidal neovascularization. Traditional treatments used to include laser photocoagulation or photodynamic therapy. Over the past few years, anti-VEGF therapies have been used as an alternative treatment. The case of a 54-year-old patient who received anti-VEGF therapy (ranibizumab) for the treatment of choroidal neovascularization secondary to angioid streaks is reported. The patient received two injections that led to complete resolution of intraretinal fluid and reduction in lesion size. After 1 year of follow-up, the patient has presented no recurrence. This case illustrates the efficacy of intravitreal anti-VEGF therapy for choroidal neovascularization in angioid streaks. Further prospective studies on a larger number of patients should help establish the best treatment and follow-up strategies.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Angioid Streaks / complications
  • Angioid Streaks / diagnosis
  • Angioid Streaks / drug therapy*
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Choroidal Neovascularization / diagnosis
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Male
  • Middle Aged
  • Ranibizumab

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Ranibizumab